Skip to content
Descubridor Institucional UMAR
Inicio
Búsqueda avanzada
Explorar
Inicio
Búsqueda avanzada
Explorar
Login
Language
English
Deutsch
Español
Français
Italiano
All Fields
Title
Author
Subject
Call Number
ISBN/ISSN
Tag
Find
Advanced
Revised "iRR6" model in intermediate-1 risk myelofibrosis patients treated with ruxolitinib
Revised "iRR6" model in intermediate-1 risk myelofibrosis patients treated with ruxolitinib
Fuente:
Zenodo
Saved in:
Bibliographic Details
Main Authors:
PALANDRI, FRANCESCA
,
Branzanti, Filippo
,
ded, Alessandra
Format:
Recurso digital
Published:
Zenodo
2024
Online Access:
Acceder al recurso
Tags:
Add Tag
No Tags, Be the first to tag this record!
Cite this
Text this
Email this
Print
Export Record
Export to RefWorks
Export to EndNoteWeb
Export to EndNote
Save to List
Permanent link
Holdings
Description
Comments
Similar Items
Staff View
Internet
https://doi.org/10.5281/zenodo.14017637
Similar Items
Survival and quality‐of‐life implications of cytopenia trajectories in ruxolitinib‐treated myelofibrosis
by: Francesca Palandri, et al.
Published: (2026)
Neutrophil to lymphocyte ratio in myelofibrosis patients treated with ruxolitinib may predict prognosis and rate of discontinuation
by: Alessandro Laganà, et al.
Published: (2024)
Oral administration of ruxolitinib in psoriasis vulgaris: A case report of plaque psoriasis accompanied by myelofibrosis secondary to polisitemia vera successfully treated with oral ruxolitinib
by: Tubanur Çetinarslan, et al.
Published: (2024)
Exposure–response relationship of fedratinib in patients with intermediate‐2 or high‐risk myelofibrosis
by: Yizhe Chen, et al.
Published: (2025)
Dosing and clinical outcomes of ruxolitinib in patients with myelofibrosis in a real‐world setting: Interim results of the Italian observational study (ROMEI)
by: Massimo Breccia, et al.
Published: (2025)